文献速递炎症性肠病

维得利珠单抗治疗溃疡性结肠炎结局预测临床评分工具的开发与验证

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-02-13

基于GEMINI 1试验620例溃疡性结肠炎患者数据开发维得利珠单抗疗效预测评分工具(CDST),并在美国常规实践199例患者中验证。无TNF拮抗剂暴露、病程≥2年、基线内镜活动中度及白蛋白水平与无激素缓解独立相关,CDST可识别高概率应答者及可能从缩短给药间隔获益的患者。

要点

  • CDST评分≤26分可高敏感性识别维得利珠单抗无应答者。
  • 低、中概率组可能从因初始无应答而缩短给药间隔中获益。
  • CDST不能识别抗TNF治疗期间获得无激素缓解的患者。

核心结论

  • CDST可识别维得利珠单抗治疗中最可能达到无激素缓解的UC患者,但不能识别抗TNF治疗的无激素缓解者。

研究设计与样本

  • 对GEMINI 1试验中620例接受维得利珠单抗诱导和维持治疗的UC患者数据进行逻辑回归分析(推导队列)。

主要发现

  • 无TNF拮抗剂暴露(+3分)、病程≥2年(+3分)、基线内镜活动中度vs重度(+2分)、基线白蛋白浓度(每1 g/L +0.65分)与无激素缓解独立相关。
  • 推导队列中概率分组与疗效(ROC曲线下面积0.65)及药物暴露(P < .001)呈显著线性关系。
  • 验证队列中,26分界值识别维得利珠单抗无应答者的敏感性为93%;仅低、中概率组因缺乏应答而缩短给药间隔后获益(P = .02)。

关键数值与推荐

  • CDST评分分组:低概率≤26分,中概率27-32分,高概率≥33分。
  • 无激素缓解定义:全Mayo评分≤2分且无单项子评分>1分。

临床怎么用

  • CDST可用于预测UC患者维得利珠单抗治疗的无激素缓解概率,辅助治疗决策。
  • 对CDST低、中概率组患者,若初始无应答,可考虑缩短维得利珠单抗给药间隔。

局限性

  • CDST不能识别抗TNF治疗期间获得无激素缓解的患者。
  • 验证队列样本量有限(199例),需进一步外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We created and validated a clinical decision support tool (CDST) to predict outcomes of vedolizumab therapy for ulcerative colitis (UC). METHODS: We performed logistic regression analyses of data from the GEMINI 1 trial, from 620 patients with UC who received vedolizumab induction and maintenance therapy (derivation cohort), to identify factors associated with corticosteroid-free remission (full Mayo score of 2 or less, no subscore above 1). We used these factors to develop a model to predict outcomes of treatment, which we called the vedolizumab CDST. We evaluated the correlation between exposure and efficacy. We validated the CDST in using data from 199 patients treated with vedolizumab in routine practice in the United States from May 2014 through December 2017. RESULTS: Absence of exposure to a tumor necrosis factor (TNF) antagonist (+3 points), disease duration of 2 y or more (+3 points), baseline endoscopic activity (moderate vs severe) (+2 points), and baseline albumin concentration (+0.65 points per 1 g/L) were independently associated with corticosteroid-free remission during vedolizumab therapy. Patients in the derivation and validation cohorts were assigned to groups of low (CDST score, 26 points or less), intermediate (CDST score, 27-32 points), or high (CDST score, 33 points or more) probability of vedolizumab response. We observed a statistically significant linear relationship between probability group and efficacy (area under the receiver operating characteristic curve, 0.65), as well as drug exposure (P < .001) in the derivation cohort. In the validation cohort, a cutoff value of 26 points identified patients who did not respond to vedolizumab with high sensitivity (93%); only the low and intermediate probability groups benefited from reducing intervals of vedolizumab administration due to lack of response (P = .02). The vedolizumab CDST did not identify patients with corticosteroid-free remission during TNF antagonist therapy. CONCLUSIONS: We used data from a trial of patients with UC to develop a scoring system, called the CDST, which identified patients most likely to enter corticosteroid-free remission during vedolizumab therapy, but not anti-TNF therapy. We validated the vedolizumab CDST in a separate cohort of patients in clinical practice. The CDST identified patients most likely to benefited from reducing intervals of vedolizumab administration due to lack of initial response. ClinicalTrials.gov no: NCT00783718.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Dulai PS, Singh S, Vande Casteele N, et al. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020. PMID: 32062041. doi:10.1016/j.cgh.2020.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。